<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475447</url>
  </required_header>
  <id_info>
    <org_study_id>ASMP2006</org_study_id>
    <nct_id>NCT02475447</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis</brief_title>
  <official_title>A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tioga Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tioga Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an&#xD;
      orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in&#xD;
      several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the&#xD;
      safety, tolerability and clinical efficacy of asimadoline in patients with pruritus&#xD;
      associated with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asimadoline has been administered to over 1900 human subjects or patients in clinical trials&#xD;
      and exhibits an acceptable safety profile. Due to its high selectivity for the kappa-opioid&#xD;
      receptor, asimadoline does not produce mu-opioid like side-effects. Results from preclinical&#xD;
      models indicate asimadoline significantly reduces the frequency of scratching induced by&#xD;
      pruritic agents. This double-blind placebo-controlled clinical study is designed to evaluate&#xD;
      the safety, tolerability and clinical efficacy of asimadoline in patients with pruritus&#xD;
      associated with atopic dermatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Worst Itching Severity using a Visual Analog Scale</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax in plasma (Tmax)</measure>
    <time_frame>0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-versus-time curve (AUC) from the time of the dose to the end of the 12-hour dosing interval</measure>
    <time_frame>0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Pruritus</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matched tablets twice daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asimadoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asimadoline</intervention_name>
    <description>kappa-opioid receptor agonist</description>
    <arm_group_label>Asimadoline</arm_group_label>
    <other_name>No brand name, serial number and code name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo-matched control</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No brand name, serial number and code name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent and must be able and willing to follow study procedures and&#xD;
             instructions&#xD;
&#xD;
          2. Male or female subject aged 18 years or older (no upper age limit)&#xD;
&#xD;
          3. Established clinical diagnosis of atopic dermatitis for at least 6 months&#xD;
&#xD;
          4. Itching Visual Analog Scale (VAS) average worst itching score of at least 40 mm on a&#xD;
             100 mm scale&#xD;
&#xD;
          5. Female subject of childbearing potential and male subject of procreative capacity&#xD;
             agree to use an effective method of contraception for the duration of the study&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, attempting to conceive, or nursing&#xD;
&#xD;
          2. Received phototherapy (ultraviolet B, psoralen plus ultraviolet A) within the previous&#xD;
             4 weeks&#xD;
&#xD;
          3. Received treatment with any of the following within the previous 2 weeks:&#xD;
&#xD;
             - Topical or oral immunosuppressants or calcineurin inhibitors, sedating&#xD;
             anti-histamines or anti-histamines taken for pruritus treatment, prescription topical&#xD;
             corticosteroid creams or ointments, any other oral or topical steroids, aprepitant,&#xD;
             naltrexone, pregabalin, gabapentin, or tricyclic antidepressants, or any other&#xD;
             medications that, in the investigator's judgement, could affect the subject's pruritus&#xD;
             or atopic dermatitis, and that are not specified below&#xD;
&#xD;
             OR taking any of the following and has not been on stable use for at least the&#xD;
             previous 4 weeks:&#xD;
&#xD;
             - Non-prescription topical hydrocortisone creams or ointments, lotions, moisturizers,&#xD;
             emollients, bath oil treatments, non-sedating oral anti-histamines being taken for&#xD;
             allergy treatment, selective serotonin reuptake inhibitor (SSRI) antidepressants.&#xD;
&#xD;
          4. Currently participating in other investigational clinical studies or having received&#xD;
             investigational drugs in a clinical research study within the previous 3 months.&#xD;
             Subjects currently enrolled in an observational study are eligible for participation&#xD;
             in this study, however subjects must not enroll in a new observational study during&#xD;
             the course of their participation in this study&#xD;
&#xD;
          5. Pruritus due to conditions other than atopic dermatitis (e.g., hepatitis, biliary&#xD;
             cirrhosis, scabies) or due to medications known to cause pruritus&#xD;
&#xD;
          6. Acute illnesses, uncontrolled or unmanaged diabetes or thyroid disease, decompensated&#xD;
             heart failure, cirrhosis or liver failure, chronic kidney disease, or uncontrolled&#xD;
             psychiatric disease&#xD;
&#xD;
          7. Evidence or treatment of malignancy (other than localized basal cell cancer, squamous&#xD;
             cell skin cancer, or cancer in situ that has been resected) within the previous 5&#xD;
             years&#xD;
&#xD;
          8. History of HIV infection&#xD;
&#xD;
          9. History of alcohol or drug abuse within the past 3 years&#xD;
&#xD;
         10. Diseases or conditions that could, in the opinion of the investigator, interfere with&#xD;
             the assessment of safety and efficacy of the study drug and compliance of the subject&#xD;
             with study visits/procedures (e.g. exacerbation of multiple sclerosis or other&#xD;
             comorbid conditions)&#xD;
&#xD;
         11. Use of any product that acts as an inhibitor of P-glycoprotein (P-gp) or as a P-gp&#xD;
             substrate (with the exception of topical ketoconazole product for skin or scalp)&#xD;
             within the previous 4 weeks&#xD;
&#xD;
         12. Known allergy to asimadoline or its drug components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn McGuire, MD FAAN</last_name>
    <role>Study Director</role>
    <affiliation>Tioga Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan, MD PA</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forefront Dermatology</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSearch Clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Group</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center for Clinical Research</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Dermatology and Skin Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Department of Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple Itch Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy and Asthma Research, LLC</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

